

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all previous versions, and listings, of claims pending in this application.

Listing of Claims


1-161. (Canceled)

162. (Currently amended) A compound comprising a peptide chain having a sequence of amino acids $CX_{1}^{IV}X_{2}^{IV}X_{3}^{IV}X_{4}^{IV}X_{5}^{IV}X_{6}^{IV}X_{7}^{IV}X_{8}^{IV}X_{9}^{IV}X_{10}^{IV}$ ~~approximately 17 to 40 amino acids in length~~ that binds to a G-CSFR, ~~wherein said and contains a~~ sequence of amino acids is selected from the group consisting of GGGLLDICELKLQECARRCN (SEQ ID NO: 209); GRTGGLLDICELKLQECARRCN (SEQ ID NO: 210); LGIEGRTGGGLLDICELKLQECARRCN (SEQ ID NO: 211); LLDICEELKLQEAARRCN (SEQ ID NO: 212); LLDIAELKLQECARRCN (SEQ ID NO: 464); KLLDICEELKLQEAARRCN (SEQ ID NO: 213); and LLDICELKLQECARRAN (SEQ ID NO: 343), ~~and wherein each amino acid is indicated by standard one-letter abbreviation.~~

163. (Previously presented) The compound of claim 162, wherein said sequence of amino acids is GGGLLDICELKLQECARRCN (SEQ ID NO: 209).

164. (Previously presented) The compound of claim 162, wherein said sequence of amino acids is GRTGGLLDICELKLQECARRCN (SEQ ID NO: 210).

165. (Canceled) ~~The compound of claim 162, comprising a dimer having the structure of formula (VIII)~~



wherein R^1 and R^2 are independently selected from the sequences of amino acids of claim 1; formula (V); βA is a β alanine residue; $n1, n2, n3, n4, x$ and y are independently zero or one with the proviso that the sum of x and y is either one or two; and Lk is a terminal linking moiety selected from the group consisting of a disulfide bond, a carbonyl moiety, a C1-12 linking moiety optionally terminated with one or two NH linkages and optionally substituted at one or more available carbon atoms with a lower alkyl substituent, a lysine residue or a lysine amide.

166. (Previously presented) The compound of claim 162, containing a disulfide bond.
167. (Currently amended) The compound of ~~claim claims~~-162 wherein the N terminus of the peptide is coupled to a polyethylene glycol molecule.
168. (Previously presented) The compound of claim 162 wherein the N terminus of the peptide is acetylated.
169. (Previously presented) The compound of claim 162, wherein the C terminus of the peptide is amidated.
170. (Currently amended) A pharmaceutical composition comprising a therapeutically effective amount of the compound of ~~any claim~~-162, in combination with a pharmaceutically acceptable carrier.
171. (Withdrawn) A method for treating a patient who would benefit from administration of a GCSF modulator, comprising administering to the patient a therapeutically effective amount of the compound of claim 162.
172. (Withdrawn) The method of claim 171, wherein the G-CSF modulator is an agonist for the GCSFR.
173. (Withdrawn) The method of claim 171, wherein the patient suffers from a depressed neutrophil count.
174. (Withdrawn) The method of claim 173, wherein the depressed neutrophil count is associated with a condition selected from the group consisting of chemotherapy-induced neutropenia, AIDS induced neutropenia and community-acquired pneumonia-induced neutropenia.
175. (Previously presented) The compound of claim 162, wherein said sequence of amino acids is LGIEGRTGGGLLDICELKQECARRCN (SEQ ID NO: 211).
176. (Previously presented) The compound of claim 162, wherein said sequence of amino acids is LLDICEELKLQEAARRCN (SEQ ID NO: 212).
177. (Currently amended)Previously presented) The compound of claim 162, wherein said sequence of amino acids is LLDIAELKLQECARRCN (SEQ ID NO: 464), ~~LLDICEELKLQEAARRCN (SEQ ID NO: 213)~~.

178. (Previously presented) The compound of claim 162, wherein said sequence of amino acids is LLDICELKLQECARRAN (SEQ ID NO:343).